Rachel N. Grisham - Concepedia

Author

Rachel N. Grisham

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

R Grisham, R. Grisham, R. N. Grisham, R.N. Grisham, Rachel Grisham, Rachel N Grisham, Rachel N. Grisham, Rachel Nicole Grisham

271

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University European Institute of Oncology The University of Texas MD Anderson Cancer Center The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

About

Rachel N. Grisham is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	25	1.9K
2	Cell Biology	2	2	72
3	Health Sciences	1	1	50
4	Natural Sciences	1	1	38
5	Public Health	1	1	63

Rachel N. Grisham

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum‐Gamez, Journal of the National Comprehensive Cancer Network Surgical OncologyEpithelial Ovarian CancerCancer ManagementPelvic Reconstructive SurgeryGynecology	2021	688
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022 Deborah K. Armstrong, Ronald D. Alvarez, Floor Backes, Journal of the National Comprehensive Cancer Network Nccn Guidelines® InsightsTumoral PathologyEndocrine-related CancerEpithelial Ovarian CancerMedicine	2022	369
Ovarian cancer mutational processes drive site-specific immune evasion Ignacio Vázquez-Garćıa, Florian Uhlitz, Nicholas Ceglia, Nature	2022	260
BRAF Mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer Rachel N. Grisham, Gopa Iyer, Karuna Garg, Cancer	2012	219
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer Tara E. Soumerai, Mark T.A. Donoghue, Chaitanya Bandlamudi, Clinical Cancer Research	2018	163
MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum Bradley J. Monk, Rachel N. Grisham, Susana Banerjee, Journal of Clinical Oncology	2020	144
Clinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy Jasmine H. Francis, Larissa A. Habib, David H. Abramson, Ophthalmology Diabetic RetinopathyOcular DiseaseMek Inhibitor–associated RetinopathyOphthalmologyPathology	2017	129
Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study Oliver Zivanovic, S. Dennis, Qin Zhou, Journal of Clinical Oncology	2021	117
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer Rachel N. Grisham, Brooke E. Sylvester, Helen Won, Journal of Clinical Oncology	2015	106
Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000–2013 Anton Oseledchyk, Mario M. Leitão, Jason Konner, Annals of Oncology MedicineAdjuvant ChemotherapyGynecologyCell Ovarian CancerCancer Treatment	2017	89

Page 1